Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

Español • Italiano • Sardu • English | PDF+


  Tuberculosis

  Free Subscription


Articles published in PLoS Med

Retrieve available abstracts of 44 articles:
HTML format
Text format



Single Articles


    July 2019
  1. SCHUTZ C, Barr D, Andrade BB, Shey M, et al
    Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study.
    PLoS Med. 2019;16:e1002840.
    PubMed     Text format     Abstract available


  2. DOOLEY KE, Hanna D, Mave V, Eisenach K, et al
    Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.
    PLoS Med. 2019;16:e1002842.
    PubMed     Text format    


  3. OLLIARO PL, Vaillant M
    Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.
    PLoS Med. 2019;16:e1002850.
    PubMed     Text format     Abstract available


  4. DAVIES G, Boeree M, Hermann D, Hoelscher M, et al
    Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
    PLoS Med. 2019;16:e1002851.
    PubMed     Text format     Abstract available


  5. PENN-NICHOLSON A, Hraha T, Thompson EG, Sterling D, et al
    Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
    PLoS Med. 2019;16:e1002880.
    PubMed     Text format     Abstract available


    June 2019
  6. CAMPBELL JR, Dowdy D, Schwartzman K
    Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries.
    PLoS Med. 2019;16:e1002824.
    PubMed     Text format     Abstract available



  7. Correction: Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation.
    PLoS Med. 2019;16:e1002823.
    PubMed     Text format     Abstract available


    May 2019
  8. LALVANI A, Berrocal-Almanza LC, Halliday A
    Predicting progression to active tuberculosis: A rate-limiting step on the path to elimination.
    PLoS Med. 2019;16:e1002814.
    PubMed     Text format     Abstract available


  9. KLEIN K, Bernachea MP, Iribarren S, Gibbons L, et al
    Correction: Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study.
    PLoS Med. 2019;16:e1002826.
    PubMed     Text format     Abstract available


    April 2019
  10. GUPTA-WRIGHT A, Corbett EL, Wilson D, van Oosterhout JJ, et al
    Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study.
    PLoS Med. 2019;16:e1002776.
    PubMed     Text format     Abstract available


  11. STRYDOM N, Gupta SV, Fox WS, Via LE, et al
    Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    PLoS Med. 2019;16:e1002773.
    PubMed     Text format     Abstract available


  12. KAWASAKI M, Echiverri C, Raymond L, Cadena E, et al
    Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.
    PLoS Med. 2019;16:e1002780.
    PubMed     Text format     Abstract available


  13. PENN-NICHOLSON A, Hraha T, Thompson EG, Sterling D, et al
    Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
    PLoS Med. 2019;16:e1002781.
    PubMed     Text format     Abstract available


  14. CHURCHYARD GJ, Swindells S
    Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB.
    PLoS Med. 2019;16:e1002787.
    PubMed     Text format     Abstract available


  15. WARSINSKE H, Vashisht R, Khatri P
    Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures.
    PLoS Med. 2019;16:e1002786.
    PubMed     Text format     Abstract available


  16. VEKEMANS J, O'Brien KL, Farrar J
    Tuberculosis vaccines: Rising opportunities.
    PLoS Med. 2019;16:e1002791.
    PubMed     Text format     Abstract available


  17. MANJALY THOMAS ZR, Satti I, Marshall JL, Harris SA, et al
    Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    PLoS Med. 2019;16:e1002790.
    PubMed     Text format     Abstract available


  18. COLMAN RE, Mace A, Seifert M, Hetzel J, et al
    Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation.
    PLoS Med. 2019;16:e1002794.
    PubMed     Text format     Abstract available


  19. KLEIN K, Bernachea MP, Irribarren S, Gibbons L, et al
    Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study.
    PLoS Med. 2019;16:e1002788.
    PubMed     Text format     Abstract available


  20. GARCIA-PRATS AJ, Schaaf HS, Draper HR, Garcia-Cremades M, et al
    Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    PLoS Med. 2019;16:e1002789.
    PubMed     Text format     Abstract available


  21. HATHERILL M, Chaisson RE, Denkinger CM
    Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies.
    PLoS Med. 2019;16:e1002795.
    PubMed     Text format     Abstract available


    March 2019
  22. MABUD TS, de Lourdes Delgado Alves M, Ko AI, Basu S, et al
    Correction: Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil.
    PLoS Med. 2019;16:e1002764.
    PubMed     Text format     Abstract available


  23. PHILLIPS PPJ, Mitnick CD, Neaton JD, Nahid P, et al
    Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
    PLoS Med. 2019;16:e1002767.
    PubMed     Text format     Abstract available


    February 2019
  24. SUBBARAMAN R, Nathavitharana RR, Mayer KH, Satyanarayana S, et al
    Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care.
    PLoS Med. 2019;16:e1002754.
    PubMed     Text format     Abstract available


    January 2019
  25. MABUD TS, de Lourdes Delgado Alves M, Ko AI, Basu S, et al
    Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil.
    PLoS Med. 2019;16:e1002737.
    PubMed     Text format     Abstract available


    September 2018
  26. SUTHAR AB, Moonan PK, Alexander HL
    Towards national systems for continuous surveillance of antimicrobial resistance: Lessons from tuberculosis.
    PLoS Med. 2018;15:e1002658.
    PubMed     Text format     Abstract available


  27. KWAN A, Daniels B, Saria V, Satyanarayana S, et al
    Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities.
    PLoS Med. 2018;15:e1002653.
    PubMed     Text format     Abstract available


    August 2018
  28. MCINTOSH AI, Jenkins HE, White LF, Barnard M, et al
    Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.
    PLoS Med. 2018;15:e1002638.
    PubMed     Text format     Abstract available


    July 2018
  29. ALIPANAH N, Jarlsberg L, Miller C, Linh NN, et al
    Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.
    PLoS Med. 2018;15:e1002595.
    PubMed     Text format     Abstract available


  30. HARAUSZ EP, Garcia-Prats AJ, Law S, Schaaf HS, et al
    Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    PLoS Med. 2018;15:e1002591.
    PubMed     Text format     Abstract available


    March 2018
  31. PAI M
    Time for high-burden countries to lead the tuberculosis research agenda.
    PLoS Med. 2018;15:e1002544.
    PubMed     Text format     Abstract available


    December 2017
  32. KENDALL EA, Schumacher SG, Denkinger CM, Dowdy DW, et al
    Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study.
    PLoS Med. 2017;14:e1002472.
    PubMed     Text format     Abstract available


    November 2017
  33. RUDGARD WE, Evans CA, Sweeney S, Wingfield T, et al
    Comparison of two cash transfer strategies to prevent catastrophic costs for poor tuberculosis-affected households in low- and middle-income countries: An economic modelling study.
    PLoS Med. 2017;14:e1002418.
    PubMed     Text format     Abstract available


  34. SHETE PB, Dowdy DW
    Measuring success: The challenge of social protection in helping eliminate tuberculosis.
    PLoS Med. 2017;14:e1002419.
    PubMed     Text format     Abstract available


  35. YATES TA, Tomlinson LA, Bhaskaran K, Langan S, et al
    Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.
    PLoS Med. 2017;14:e1002457.
    PubMed     Text format     Abstract available


    October 2017
  36. DATTA S, Saunders MJ, Tovar MA, Evans CA, et al
    Improving tuberculosis diagnosis: Better tests or better healthcare?
    PLoS Med. 2017;14:e1002406.
    PubMed     Text format     Abstract available


  37. SYLVIA S, Xue H, Zhou C, Shi Y, et al
    Tuberculosis detection and the challenges of integrated care in rural China: A cross-sectional standardized patient study.
    PLoS Med. 2017;14:e1002405.
    PubMed     Text format     Abstract available


    February 2017
  38. COX H, Dickson-Hall L, Ndjeka N, Van't Hoog A, et al
    Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    PLoS Med. 2017;14:e1002238.
    PubMed     Text format     Abstract available


    January 2017
  39. KENDALL EA, Shrestha S, Cohen T, Nuermberger E, et al
    Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
    PLoS Med. 2017;14:e1002202.
    PubMed     Text format     Abstract available


    October 2016
  40. CASALI N, Broda A, Harris SR, Parkhill J, et al
    Whole Genome Sequence Analysis of a Large Isoniazid-Resistant Tuberculosis Outbreak in London: A Retrospective Observational Study.
    PLoS Med. 2016;13:e1002137.
    PubMed     Text format     Abstract available


  41. KUNKEL A, Cobelens FG, Cohen T
    Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    PLoS Med. 2016;13:e1002142.
    PubMed     Text format     Abstract available


  42. SUBBARAMAN R, Nathavitharana RR, Satyanarayana S, Pai M, et al
    The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis.
    PLoS Med. 2016;13:e1002149.
    PubMed     Text format     Abstract available


  43. HOUBEN RM, Dodd PJ
    The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.
    PLoS Med. 2016;13:e1002152.
    PubMed     Text format     Abstract available


    August 2016
  44. BINAGWAHO A, Kankindi I, Kayirangwa E, Nyemazi JP, et al
    Transitioning to Country Ownership of HIV Programs in Rwanda.
    PLoS Med. 2016;13:e1002075.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: